HALAVEN® for the treatment of metastatic breast cancer



As a patient with metastatic breast cancer

It’s important
to know
your options

It’s time to
learn if
Halaven^® is
right for you

Visit
halaven.com

Prescribing Info
Safety Info

Who is HALAVEN^® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

• Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5&#730F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection.
• Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy
• Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

• have liver or kidney problems
• have heart problems, including a problem called congenital long QT syndrome
• have low potassium or low magnesium in your blood
• are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3&#189 months (14 weeks) after the final dose of HALAVEN
• are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?
HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

HALAVEN^® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2016 Eisai Inc. All rights reserved. July 2016 HALA-US0482 us.eisai.com

 HALAVEN® for the treatment of metastatic breast cancer

Although some women lived longer and some women did not live as long, women with metastatic breast cancer (mBC) who were treated with HALAVEN in a clinical trial lived an average of 13.2 months compared with women treated with other chemotherapy or hormone therapy, who lived an average of 10.6 months.